Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News Phase III evidence elevates BREZTRI in the competitive asthma landscape Phase III data position AstraZeneca Plc’s BREZTRI for asthma growth. Discover the strategic, financial, and competitive implications. bySoujanya RaviFebruary 15, 2026